# The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

> **NCT02627820** · PHASE2 · WITHDRAWN · sponsor: **Brigham and Women's Hospital**

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Isis 420915/GSK 299872

## Key facts

- **NCT ID:** NCT02627820
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-08-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02627820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02627820, "The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02627820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*